(MedPage Today) — For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major cardiovascular adverse events (MACE) for those taking ustekinumab (Stelara) versus vedolizumab (Entyvio), according…
Source link : https://www.medpagetoday.com/meetingcoverage/ccc/114157
Author :
Publish date : 2025-02-10 19:20:17
Copyright for syndicated content belongs to the linked Source.
